Linezolid Tablets 300 mg (Linezolid)

Adult dose

Nosocomial pneumonia: Administer 600mg orally every 12 hours Administer continuously for 10-14 days Community-acquired pneumonia (including cases with bacteremia), complicated skin and soft tissue infections, and uncomplicated skin and soft tissue infections: Adults: Administer 400mg orally every 12 hours Administer continuously for 10-14 days Vancomycin-resistant Enterococcus faecium infections (including cases with bacteremia): Administer 600mg orally every 12 hours Administer continuously for 14-28 days Adult patients with infections caused by methicillin-resistant Staphylococcus aureus (MRSA) should receive 600 mg of this medicine every 12 hours. If oral treatment is clinically indicated in patients who began treatment with the injectable formulation, the physician may switch them to the oral formulation at their discretion. No dose adjustment is necessary. To reduce the development of drug-resistant bacteria and maintain the effectiveness of this medicine and other antibiotics, this medicine should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, it should be considered when selecting or modifying antibiotic therapy. The maximum duration of treatment with this medicine is 28 days. The safety and efficacy of treatment for more than 28 days have not been established.

Child dose

Nosocomial pneumonia: Children (newborns to 11 years): Administer 10mg per kg of body weight orally every 8 hours Community-acquired pneumonia (including cases with bacteremia), complicated skin and soft tissue infections, and uncomplicated skin and soft tissue infections: Under 5 years: Administer 10mg per kg of body weight orally every 8 hours Community-acquired pneumonia (including cases with bacteremia), complicated skin and soft tissue infections, and uncomplicated skin and soft tissue infections: 5-11 years: Administer 10mg per kg of body weight orally every 12 hours Community-acquired pneumonia (including cases with bacteremia), complicated skin and soft tissue infections, and uncomplicated skin and soft tissue infections: Adolescents (12-17 years): Administer 600mg orally every 12 hours Vancomycin-resistant Enterococcus faecium infections (including cases with bacteremia): Children (newborns to 11 years): Administer 10mg per kg of body weight orally every 8 hours Vancomycin-resistant Enterococcus faecium infections (including cases with bacteremia): Adolescents and adults (12 years and older): Administer 600mg orally every 12 hours * Newborns less than 7 days old: Most preterm neonates less than 7 days old (born at 34 weeks' gestation or earlier) have lower systemic clearance and higher AUC of this medicine than full-term newborns and infants. These newborns should be started on a dose of 10 mg per kg of body weight every 12 hours. For newborns whose clinical response is less than optimal, administration of 10 mg/kg every 8 hours may be considered. All neonatal patients should receive 10 mg per kg of body weight every 8 hours through 7 days of age.

This medication may cause myelosuppression, leading to a decrease in blood cell counts; therefore, regular blood tests should be performed, especially with long-term use exceeding 2 weeks. If diarrhea occurs after antibiotic use, there could be a suspicion of pseudomembranous colitis, so medical personnel must be informed immediately. This drug is not effective against certain gram-negative bacterial infections, so if such an infection is suspected, appropriate alternative treatments should be sought. Diabetic patients taking this medication should closely monitor their blood glucose levels due to the potential for hypoglycemic symptoms. This medication should not be used in patients who are allergic to it or its components, or who are taking certain MAO inhibitors. Patients with uncontrolled hypertension or conditions such as hyperthyroidism should discuss the use of this drug with their healthcare provider. This drug should be used with caution in children and in patients with reduced kidney or liver function, and dosage adjustments may be necessary. Common symptoms during treatment include headaches, diarrhea, nausea, etc., and if severe adverse reactions occur, healthcare personnel should be notified immediately. Long-term use of this drug may lead to peripheral neuropathy or ocular nerve issues, so an immediate examination is required if changes in vision occur. This drug may interact with other medications; therefore, patients should inform their healthcare provider of any other medications they are taking. Pregnant or lactating women should consult their healthcare provider before using this drug, and breastfeeding should be avoided during the treatment period. In case of overdose, immediate medical attention is required, and this drug can be partially removed via hemodialysis. This drug should be stored out of reach of children, and it is advisable not to transfer it to other containers. If any unusual symptoms or discomfort occur during treatment, it is important to consult medical personnel immediately.

Anemia, leukopenia, pancytopenia, thrombocytopenia, colitis with pseudomembranes, diarrhea, headache, nausea, candidiasis, fungal infection, fever, dizziness, insomnia, taste disturbance, vomiting, abdominal pain, constipation, dyspepsia, tongue discoloration, hypertension, neutropenia, vaginal candidiasis, rash, itching, abnormal liver function tests, eosinophilia, upper respiratory tract infection, pharyngitis, cough, sepsis, trauma, localized pain, convulsion, gastrointestinal bleeding, oral candidiasis, thrombocytosis, dyspnea, pneumonia, apnea, hypokalemia, peripheral neuropathy, vision loss, angioedema, anaphylaxis, Stevens-Johnson syndrome, thrombocytopenia, hemoglobin reduction, leukopenia, neutropenia, leukocytosis, disseminated intravascular coagulation, increased INR, increased aPTT, left shift of leukocyte differential count, hemoperitoneum, exacerbation of acute myeloid leukemia, exacerbation of leukemia, exacerbation of acute lymphoblastic leukemia, exacerbation of multiple myeloma, progression of malignant lymphoma, exacerbation of colitis with pseudomembranes, intestinal ulcer, bloody stools, recurrence of esophageal cancer, gastric cancer, respiratory failure, pulmonary hemorrhage, acute respiratory distress syndrome, pulmonary edema, pneumothorax, acute interstitial pneumonia, acute respiratory failure, exacerbation of empyema, worsening of hypoxia, lung infection, stridor, ventricular tachycardia, tachycardia, atrial fibrillation, myocardial infarction, exacerbation of heart failure, cardiac arrest, exacerbation of acute cardiopulmonary failure, arrhythmia, recurrence of myocardial infarction, hypotension, hyponatremia, hyperkalemia, worsening of hypokalemia, worsening of hypocalcemia, convulsion, sensory loss, anxiety, depression, meningitis, progression and exacerbation of subdural hemorrhage, intraventricular hemorrhage, cerebrovascular disorder, variceal hemorrhage, exacerbation of thrombotic microangiopathy, foot drop, progression of pyogenic arthritis, hyperthyroidism, exacerbation of graft-versus-host disease, septic shock, co-infection, multiple organ failure, infection, bacteremia, shingles, fungal bloodstream infection, decreased treatment response, candidemia, skin and soft tissue infection, thrombocytopenia, hemoglobin reduction, leukopenia, neutropenia, abnormal liver function tests, dental discoloration, neuropathy, pulmonary function failure, worsening of liver failure, optic neuropathy, appendiceal cancer

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, preferably in a cool place between 15 and 30 degrees Celsius. Proper storage will help maintain the drug's efficacy for a longer period.

Appearance

White, convex oval film-coated tablets

Package unit

10 tablets/bottle